Siltuximab administration results in spurious IL‐6 elevation in peripheral blood

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

(2022) Frits van Rhee et al.   Blood Advances

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

(2022) Sheila K. Pierson et al.   Nature Communications

Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease

(2021) Sheila K. Pierson et al.   Blood Advances

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

(2018) Frits van Rhee et al.   BLOOD

Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy

(2016) Fang Chen et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Mechanistic Pharmacokinetic/Target Engagement/Pharmacodynamic (PK/TE/PD) Modeling in Deciphering Interplay Between a Monoclonal Antibody and Its Soluble Target in Cynomolgus Monkeys

(2013) Weirong Wang et al.   AAPS Journal